FDA Warns CustomRX Facility for Cleanroom, Potency Testing

Drug Industry Daily
A A
The FDA issued a warning to CustomRX of Wichita, Kansas, for serious deficiencies identified during an inspection of its compounding facility, including inadequate cleanroom conditions and product testing.

To View This Article:

Login

Subscribe To Drug Industry Daily